Charge
In 2019, NCATS established a Cures Acceleration Network Review Board (CAN RB) working group to assess how NCATS can accelerate translational science implementation and foster the uptake of mature CAN RB-supported tools and technologies into real-world use and practice.
The CAN RB Real-World Applications for Mature Programs (RAMP) working group is charged with making recommendations that will enable NCATS to better leverage the power and authorities of the CAN RB to transition translational science projects towards real-world utilization in vehicles that are independent of NCATS support.
The CAN RB RAMP working group will provide input on how NCATS might best transition the current 4 CAN RB mature programs towards real-world applications and make recommendations on general principles that inform the design, selection and prioritization of new projects such that facilitating transition to real-world applications is built into future project proposals.
The CAN RB RAMP working group is currently in progress and is expected to deliver formal recommendations to the CAN RB in spring 2021.
Related Reports
“Maximizing the Goals of the Cures Acceleration Network to Accelerate the Development of New Drugs and Diagnostics: A Workshop” took place June 4–5, 2012. Review the workshop summary (PDF - 601KB) or visit the National Academy of Medicine (formerly the Institute of Medicine) website for more information about this event.
Roster
CO-CHAIRS
- Chairperson
Ronald J. Bartek, M.A.
Co-Founder and Founding President
Friedreich’s Ataxia Research Alliance
Arlington, Virginia
- Vice Chairperson
Gilbert “Lynn” Marks, M.D.
Senior Advisor
Tunnell Government Services
Cape May, New Jersey
MEMBERS
- Margaret Anderson
Managing Director
Deloitte Consulting, LLP
Rosslyn, Virginia
- Christopher Flores, Ph.D.
Vice President, Neuroscience Therapeutic Area
Janssen Research & Development
San Diego, California
- Christopher Gibson, Ph.D.
Co-Founder and CEO
Recursion Pharmaceuticals
Salt Lake City, Utah
- Kathy Hudson, Ph.D.
Founder and Consultant
Hudson Works, LLC
Washington, D.C.
- Geoffrey Ling, M.D., Ph.D.
Professor of Neurology
Johns Hopkins University
Baltimore, Maryland
- Peter Marks, M.D., Ph.D.
Director
Center for Biologics Evaluation and Research (CBER)
U.S. Food and Drug Administration
Silver Spring, Maryland
- Megan O’Boyle
Principal Investigator
Phelan-McDermid Syndrome Data Network
Arlington, Virginia
- Alan Palkowitz, Ph.D.
Senior Research Professor of Medicine
University School of Medicine
Indianapolis, Indiana
- Mary Perry, Ph.D.
Program Leader
Office of Strategic Coordination
Division of Program Coordination, Planning, and Strategic Initiatives
Office of the Director
National Institutes of Health
Bethesda, Maryland
- Elizabeth Stoner, M.D.
Executive Partner
MPM Capital
New York, New York
- Laura Lyman Rodriguez, Ph.D.
Interim Chief Program Support Officer, Senior Advisor to the Executive Director
Patient-Centered Outcomes Research Institute
Washington, D.C.
- David Wholley, M.Phil.
Senior Vice President, Research Partnerships
Foundation for the National Institutes of Health
Bethesda, Maryland
EX OFFICIO
- Anna Ramsey-Ewing, Ph.D.
Director
Office of Grants Management and Scientific Review
National Center for Advancing Translational Sciences
National Institutes of Health
Bethesda, Maryland
EXECUTIVE SECRETARY
- Samantha G. Jonson, M.P.S.
Dissemination and Implementation Strategy Lead
Office of the Director
National Center for Advancing Translational Sciences
National Institutes of Health
Bethesda, Maryland